Advanced Therapies Integrates is dedicated to uniting industry leaders to drive and realize the full potential of Advanced Therapies and Medicinal Products (ATMPs). The event will focus on the key innovations within complex therapeutics, cell and gene therapies, regenerative medicines and tissue therapies and identify the challenges facing the industry, such as regulatory and commercial barriers to deploying transformational changes.
Uniquely engaging the broadest possible network, including innovators, regulators, supply chain partners, equipment and technology providers, academia, industry associations, and a wide array of government funding bodies and ATMP-focused initiatives, Advanced Therapies Integrates aims to become the leading UK event for translating cutting-edge research and disruptive innovation into widespread adoption of Advanced Therapies, delivering improved patient outcomes and revolutionizing healthcare economics.
Digital technologies offer new opportunities to overcome key challenges in ATMP manufacturing, such as quality control, efficiency and sustainability. How is the UK embracing these opportunities to make ATMPs faster and more efficiently?
We need to get advanced therapies to the people who need them rapidly and cost-effectively. How can we improve the bench to bedside journey to cut costs and improve efficiencies? How can we ensure the UK sees ATMPs as an investment in our health and economy?
In the current economic environment, both public and private funders are tightening their purse strings. How can we demonstrate the health and economic benefits that would come from a return to previous levels of funding for the ATMP sector?
The UK is home to world-class innovation hubs and science parks. How do these hubs support the collaboration and sharing of facilities and expertise required for successful ATMP development?
Manufacturing ATMPs requires advanced and constantly evolving skills. How can industry and government work together to ensure the UK has the skilled workforce needed for the growth of the ATMP sector?
The R&D hub in Stevenage is home to more than 2,500 GSK people focused on discovering and developing new medicines.
The Stevenage Campus base is home to other major organisations including Stevenage Bioscience Catalyst, the Cell and Gene Therapy Manufacturing Catapult, LifeArc and Cytiva alongside a growing cluster of start-up companies.
By car:
– 20-minute drive to Luton
By train:
-21 minutes from Kings Cross
-35 Minutes from Cambridge